ORBi: Detailled Reference

Article (Scientific journals)

Effect of timing of surgery on survival after preoperative hyperfractionated accelerated radiotherapy (HART) for locally advanced rectal cancer (LARC): Is it a matter of days?

Coucke, Philippe; Notter, Markus; Matter, Maurice et al.

2006 • In Acta Oncologica, 45 (8), p. 1086-1093

Peer reviewed

Permalink
https://hdl.handle.net/2268/9850

DOI
10.1080/02841860600891317

PubMed
17118844

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

effect of timing of surgery vol 45 2006.pdf

Author postprint (107.08 kB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Aged; Aged, 80 and over; Dose Fractionation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Preoperative Care; Radiotherapy, Adjuvant; Rectal Neoplasms/pathology/radiotherapy/surgery; Retrospective Studies

Abstract :

[en] We intend to analyse retrospectively whether the time interval ("gap duration" = GD) between preoperative radiotherapy and surgery in locally advanced rectal cancer (LARC) has an impact on overall survival (OS), cancer specific survival (CSS), disease free survival (DFS) and local control (LC). Two hundred seventy nine patients with LARC were entered in Trial 93-01 (hyperfractionated accelerated radiotherapy 41.6 Gy/26 Fx BID) shortly followed by surgery. From these 250 patients are fully assessable. The median GD of 5 days was used as a discriminator. The median follow-up for all patients was 39 months. GD > 5 days was a significant discriminator for actuarial 5-years OS (69% vs 47%, p = 0.002), CSS (82% vs 57%, p = 0.0007), DFS (62% vs 41%, p = 0.0003) but not for LC (93% vs 90%, p = non-significant). In multivariate analysis, the following factors independently predict outcome; for OS: age, GD, circumferential margin (CM) and nodal stage (ypN); for CSS: GD, ypN and vascular invasion (VI); for DFS: CEA, distance to anal verge, GD, ypN and VI; for LC: CM only. Gap duration predicts survival outcome but not local control. The patients submitted to surgery after a median delay of more than 5 days had a significantly better outcome.

Disciplines :

Hematology
Oncology

Author, co-author :

Coucke, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Radiothérapie

Notter, Markus

Matter, Maurice

Fasolini, Fabrizio

Calmes, Jean-Marie

Schlumpf, Rolph

Schwegler, N.

Stamm, B.

Phuoc Do, H.

Bouzourene, H.

Language :

English

Title :

Effect of timing of surgery on survival after preoperative hyperfractionated accelerated radiotherapy (HART) for locally advanced rectal cancer (LARC): Is it a matter of days?

Publication date :

December 2006

Journal title :

Acta Oncologica

ISSN :

0001-6381

Publisher :

Taylor & Francis

Volume :

45

Issue :

8

Pages :

1086-1093

Peer reviewed :

Peer reviewed

Available on ORBi :

since 26 March 2009

Statistics

Number of views

63 (5 by ULiège)

Number of downloads

554 (2 by ULiège)

More statistics

Scopus citations^®

25

Scopus citations^®
without self-citations

23

OpenCitations

18

Bibliography

Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986;1:1479-82.
Heald RJ, Moran BJ, Ryall RDH, et al. The Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg 1998;133:894-9.
Hermanek P, Hermanek PJ. Role of the surgeon as a variable in the treatment of rectal cancer. Sem Surg Oncol 2000;19: 329-35.
Kapiteijn E, Putter H, van de Velde CJH and cooperative investigators of the Dutch ColoRectal Cancer Group. Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. Br J Surgery 2002;89:1142-9.
MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993;341:457-60.
Martling AL, Holm T, Rutqvist L-E, et al. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Lancet 2000;356:93-6.
Quircke P, Durdey P, Dixon MF, et al. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection: Histopathological study of lateral tumor spread and surgical excision. Lancet 1986;2:996-9.
Quirke P. The pathologist, the surgeon and colorectal cancer-get it right because it matters. Prog Pathol 1998;4: 201-13.
Read TE, Myerson RJ, Fleshman JW, et al. Surgeon specialty is associated with outcome in rectal cancer treatment. Dis Colon Rectum 2002;45:904-14.
Camma C, Giunta M, Fiorica F, et al. Preoperative radiotherapy for resectable rectal cancer. JAMA 2000;284:1008-15.
Dahlberg M, Glimelius B, Pahlman L. Improved survival and reduction in local failure rates after preoperative radiotherapy: Evidence for the generalizability of the results of Swedish Rectal Cancer Trial. Ann Surg 1999;229:493-7.
Glimelius B, Isacsson U, Jung B, et al. Radiotherapy in addition to radical surgery in rectal cancer: Evidence for a dose response effect favoring preoperative treatment. Int J Radiat Oncol Biol Phys 1997;37:281-7.
Kapiteijn E, Marijnen CAM, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46.
Pahlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial. Ann Surg 1990;211:187-95.
Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336:980-7.
Coucke PA, Cuttat J-F, Mirimanoff R-O. Adjuvant postoperative accelerated hyperfractionated radiotherapy in rectal cancer: A feasibility study. Int J Radiat Oncol Biol Phys 1993;27:885-9.
Coucke PA, Sartorelli B, Cuttat J-F, et al. The rationale to switch from postoperative hyperfractionated accelerated radiotherapy to preoperative hyperfractionated accelerated radiotherapy in rectal cancer. Int J Radiat Oncol Biol Phys 1995;32:181-8.
Coucke PA, Notter M, Stamm B, et al. Preoperative hyperfractionated accelerated radiotherapy (HART) in locally advanced rectal cancer (LARC) immediately followed by surgery. A prospective phase II trial. Radiother Oncol 2006; (in press).
Hruby G, Barton M, Miles S, et al. Sites of local recurrence after surgery, with or without chemotherapy, for rectal cancer: Implications for radiotherapy design. Int J Radiat Oncol Biol Phys 2003;55:138-43.
Steup WH, Moriya Y, van de Velde CJH. Patterns of lymphatic spread in rectal cancer. A topographical analysis on lymph node metastases. Eur J Canc 2002;38:911-8.
Topor B, Ackland R, Kolodko V, et al. Mesorectal lymph nodes: Their location and distribution within the mesorectum. Dis Colo Rectum 2003;46:779-85.
Gunderson LL, Russell HA, Llewellynn HJ, et al. Treatment planning for colorectal cancer. Radiation and surgical techniques and value of small bowel films. Int J Radiat Oncol Biol Phys 1985;11:1379-93.
Brown G, Radcliffe AG, Newcombe RG, et al. Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surgery 2003; 90:355-64.
Brown G, Richards CJ, Bourne MW, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathological comparison. Radiology 2003;227:371-7.
François Y, Nemoz C, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery in downstaging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R90-01 randomized trial. J Clin Oncol 1999;17:2396-402.
Stein DE, Mahmoud NN, Rani Anné PR, et al. Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma. Dis Colon Rectum 2003;46:448-53.
Graf W, Dahlberg M, Osman MM, et al. Short-term preoperative radiotherapy results in down-staging of rectal cancer: A study of 1316 patients. Radiother Oncol 1997;43: 133-7.
Marijnen CAM, Nagtegaal ID, Klein Kranenbarg, et al. No downstaging after short term-preoperative radiotherapy in rectal cancer. J Clin Oncol 2001;19:1976-84.
Onaitis MW, Noone RB, Fields R, et al. Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Ann Surg Oncol 2001;8:801-6.
Marijnen CAM, Nagtegaal ID, Kapiteijn E, et al. Radiotherapy does not compensate for positive resection margins in rectal cancer patients: Report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys 2003;55:1311-20.
Nagtegaal ID, Marijnen CAM, Klein Kranenbarg E, et al. Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma. Am J Surg Path 2002;26:350-7.
Wiggers T, van de Velde CJH. The circumferential margin in rectal cancer: Recommendations based on the Dutch Total Mesorectal Excision Study. Eur J Cancer 2002;38:973-6.
Köckerling F, Reymond MA, Altendorf-Hofmann A, et al. Influence of surgery on metachronous distant metastasis and survival in rectal cancer. J Clin Oncol 1998;16:324-9.
Chmielarz A, Kryj M, Wloch J, et al. Prognostic factors for the time of occurrence and dynamics of distant metastases and local recurrences after radical treatment in patients with rectal cancer. Med Sci Monit 2001;7:1266-9.
Nozue M, Isaka N, Fukao K. Over-expression of vascular endothelial growth after preoperative radiation therapy for rectal cancer. Oncol Rep 2001;8:1247-9.
Krishnamachary B, Berg-Dixon S, Kelly B, et al. Regulation of colon carcinoma cell invasion by Hypoxia-Inducible Factor I. Cancer Res 2003;63:1138-43.
Bouzourene H, Chaubert P, Gebhard S, et al. Role of methallotionein in irradiated human rectal carcinoma. Cancer 2002;95:1003-8.
Miranda A, Janssen L, van Duijn W, et al. Prognostic significance of methallothionein in human gastrointestinal cancer. Clin Can Res 2002;8:1889-96.
Gorski DH, Mauceri HJ, Salloum RM, et al. Prolonged treatment with angiostatin reduces metastatic burden during radiation therapy. Cancer Res 2003;63:308-11.
Collins TS, Hurwitz HI. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Semin Oncol 2005;32:61-8.
Sanborn RE, Sandler AB. The safety of bevacizumab. Expert Opin Drug Saf 2006;5:289-301.
Nygren P, Sorbye H, Österlund P, et al. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report. Acta Oncol 2005;44:203-17.
Hoff PM. Future directions in the use of antiangiogenic agents in patients with colorectal cancer. Semin Oncol 2004; 31(Suppl 17):17-21.
Kumar A, Collins HM, Scholefield JH, et al. Increased type-IV collagenase (MMP-2 and MMP-9) activity following preoperative radiotherapy in rectal cancer. Br J Cancer 2000; 82:960-5.
Kumar A, Collins H, Van Tam J, et al. Effect of preoperative radiotherapy on matrisylin gene expression in rectal cancer. Eur J Cancer 2002;38:505-10.
Johnson MD, Kim HR, Chesler L, et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 1994;160:194-202.
Speake WJ, Dean RA, Kumar A, et al. Radiation induced MMP expression from rectal cancer is short lived but contributes to in vitro invasion. Eur J Surg Oncol 2005;31: 869-74.
Maniwa Y, Okada M, Ishii N, et al. Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer. Chest 1998;114:1668-75.
Rödel C, Haas J, Groth A, et al. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: Surviving as a radioresistance factor. Int J Radiat Oncol Biol Phys 2003;55:1341-7.

Similar publications